Context: Data on longitudinal changes of computed tomography (CT)-determined visceral fat area (VFA), skeletal muscle area (SMA) and skeletal muscle radiodensity (SMD) after adrenalectomy are limited in patients with hypercortisolism.
| INTRODUC TI ON
Chronic exposure to excess cortisol is known to be associated with elevated risk of mortality and metabolic complications.
1,2 The association was found not only in patients with overt Cushing's syndrome (CS), but also in patients with adrenal incidentalomas and mild autonomous cortisol excess (MACE), who lack the typical external characteristics of CS. [3] [4] [5] Surgical treatment in patients with MACE was also associated with improvement of metabolic risk factors. 6 However, the clinical definition of MACE is still under debate, partly due to the possibility of false positives in biochemical testing in patients with mild cortisol excess, and unclear individual prognostic implications following surgical intervention.
6,7
Considering the substantial burden of MACE, finding sensitive, reproducible markers that can reflect subtle changes after normalization of cortisol excess is needed to better identify individuals who might benefit from intervention at earlier stages. 3, 4 Changes in body composition, including accumulation of visceral fat and progressive loss of skeletal muscle, are the hallmark of chronic hypercortisolism. 1 Debono and Delivanis demonstrated that the severity of hypercortisolism was associated with higher computed tomography (CT)-determined visceral fat mass and lower trunk skeletal muscle mass in patients with adrenal adenomas.
7,8
Yener reported CT-measured visceral fat area (VFA) accumulation during a 3-year follow-up in patients with MACE. 9 These findings suggest that CT-based body composition parameters may potentially serve as markers for both the severity of cortisol excess.
However, data on longitudinal changes of CT-based VFA and skeletal muscle area (SMA) after surgical intervention according to severity of cortisol excess are limited in patients with adrenal incidentalomas.
In addition, changes of skeletal muscle radiodensity (SMD; muscle radiation attenuation in hounsfield units [HU] ), a muscle quality marker which is inversely associated with intramuscular fat content, have rarely been investigated in patients with autonomous cortisol excess. 10 Skeletal muscle radiation attenuation is a radiologic, quantifiable index of muscle fat contents based on characteristic attenuation of X-rays in different tissues. 10 SMD can be calculated as the mean HU value of all pixels included in SMA of interest and low SMD is known to be associated with accumulation of lipid, reduced muscle function and insulin resistance. [11] [12] [13] In this retrospective cohort study, we sought to determine if the severity of cortisol excess is associated with greater improvement of CT-based body composition parameters, including VFA, SMA and SMD, after adrenalectomy in patients with hypercortisolism, in comparison with patients with nonfunctioning adrenal tumours (NFATs).
| MATERIAL S AND ME THODS

| Data source
We reviewed a retrospective cohort of all patients who underwent adrenalectomy at Severance Hospital in Seoul, Korea, be- HU ≥ 10 in noncontrast CT scan), and relatively large tumour size and patient preference for surgery (n = 9; range 3-3.6 cm). Pathology reports were reviewed to ascertain the diagnosis. None of the patients in the final cohort had a history of alcohol abuse or of receiving any 
| Biochemical analysis
All patients underwent biochemical testing according to standardized clinical protocols, including morning plasma ACTH concentration, 1-mg ONDST (1 mg of dexamethasone taken at 23:00
and serum cortisol level measured between 8:00 and 9:00 on the following day), and plasma free metanephrine. In patients with hypertension or hypokalaemia, plasma aldosterone-to-renin ratio was further tested. 24-hour urinary free cortisol levels were avail- Visceral-to-subcutaneous fat ratio (VSR) and skeletal muscle index (SMI; cm 2 /m 2 , SMA normalized to height 2 ) was calculated. In randomly selected 30 subjects, measurements were repeated two times by a radiology expert (main analyst) for each patient to test intraobserver reliability. To test interobserver reliability, measurements by an independent sub-analyst were compared. Both intra-and interobserver reliability (intraclass correlation coefficient [ICC] ≥0.98 for all parameters) were excellent, which was consistent with previous reports (Supporting Information Table S1 ). 17, 20 Bland-Altman plots and Passing-Bablock regression models showed good intra-and interobserver agreement for all parameters (Supporting Information Figure S2 ). Based on observed reliability and agreement, we determined to use CT-derived parameters measured by main analyst as main outcome in all subjects for this study. All CT analyses were performed as blinded to biochemical data and clinical outcomes.
| Definitions of sarcopenia, visceral obesity and comorbidities
Sarcopenia (L3 SMI: male <45.4 cm 2 /m 2 ; female <34.4 cm 2 /m 2 ) and low SMD (L3 SMD: male <38.5 HU; female <34.3 HU) were defined using threshold derived from a cohort of healthy kidney donors. 18 Visceral obesity (VFA > 100 cm 2 ) was defined based on the guideline from Japan Society of the Study of Obesity.
21
Hypertension was defined as having documented hypertension diagnosis with the use of at least 1 antihypertensive drug.
Diabetes was defined as documented diabetes diagnosis with the use of at least 1 antidiabetic drug. Dyslipidaemia was defined as documented dyslipidaemia diagnosis with the use of at least 1 lipid-lowering drug. two-way mixed effects model for intraobserver reliability; absolute agreement, two-way random effects model for interobserver reliability) with 95% confidence interval were calculated according to
| Statistical analysis
McGraw and Wong definition in 30 randomly selected subjects to test intra-and interobserver reliability of CT-based muscle and fat measurements. 23, 24 Bland-Altman plot and Passing-Bablok regression models were built to assess intra-and interobserver agreement for CT-derived parameters. 25, 26 The statistical significance level was set at 2-sided P < 0.05. All statistical analyses were performed with STATA 14.2 (Stata Corp, College Station, TX, USA). 
| RE SULTS
| Baseline clinical characteristics
| CT-determined muscle and fat parameters at baseline
At baseline, patients with overt CS had significantly higher VFA compared to patients with MACE or NFAT (Table 1; 160 vs 116 vs 121 cm 2 , P = 0.009), whereas VSR or VFA/total fat area (%) did not differ significantly between three groups. The lowest SMA, SMI and SMD values were observed in patients with overt CS, followed by patients with MACE. The differences in SMA, SMI and SMD between patients with NFAT, MACE and overt CS were all significant in each pairwise comparison (Bonferroni-corrected P < 0.05 for all).
| CT-determined muscle and fat changes after adrenalectomy
Changes in CT-determined parameters after adrenalectomy were (Table 2) . Meanwhile, VFA, SFA and VSR significantly decreased when SMA, SMI and SMD values increased in patients with overt CS after adrenalectomy (P < 0.01 for all). In patients with MACE, the decreases in VFA and SFA with increases in SMD were significant, whereas the changes in VSR, SMA and SMI were not as evident as in patients with overt CS. The adjusted mean percentage change in SMD in MACE group was significantly greater than that of patients with NFAT (+9%, 95% CI +2% to +15%
vs −3%, 95% CI −12% to +5%, P = 0.032).
| Prevalence of visceral obesity, sarcopenia, low SMD and low bone attenuation after adrenalectomy
The prevalence of CT-determined visceral obesity, sarcopenia and low SMD was compared between the baseline and a median follow-up period of 1.1 year after adrenalectomy (Figure 2 ). Patients with NFAT did not show any significant changes in the prevalence of each condition after adrenalectomy. In contrast, a substantial decrease in the prevalence of visceral obesity (81%-33%), sarcopenia (52%-15%) and low SMD (81%-56%, P < 0.05 for all)
was observed in patients with overt CS. In patients with MACE, the prevalence of low SMD decreased (50%-32%, P = 0.025), whereas the differences in visceral obesity (50%-39%, P = 0.179) and sarcopenia (21%-14%, P = 0.317) did not reach statistical significance.
| Correlation between changes in CT-determined parameters and metabolic indices
In patients with overt CS, all metabolic indices and number of medications for hypertension, diabetes, and dyslipidaemia showed significant improvement after surgical treatment (Supporting Information Table S3 ). Although improvement of blood pressure was observed in both NFAT and MACE groups, only patients with 
<0.001
Skeletal muscle radiodensity, HU 40 ± 6 36 ± 7* 29 ± 6* , †
Data are presented as mean ± standard deviation, median [interquartile range], or number (%). Continuous variables were compared by analysis of variance with Bonferroni correction for normally distributed variables and the Kruskal-Wallis test with Dunn's procedure for pairwise comparisons for variables with nonparametric distribution. Categorical variables were compared using the chi-square test. CS, overt Cushing's syndrome; eGFR, estimated glomerular filtration rate; MACE, mild autonomous cortisol excess; NFAT, nonfunctioning adrenal tumour. *P < 0.05 vs NFAT; † P < 0.05 vs MACE.
Bold text indicates a statistically significant difference between groups by one-way ANOVA.
TA B L E 1 Baseline characteristics of study subjects
| Association of post-dexamethasone serum cortisol levels with CT-determined muscle and fat changes after adrenalectomy
In Table 3 , the association of morning post-dexamethasone cortisol level with CT-determined changes of body composition parameters was analysed. Unadjusted models showed that higher post-dexamethasone cortisol levels at baseline were associated with greater reductions in VFA and VSR, and improvements in SMA, SMI and SMD values, in both absolute and relative terms. In multivariate models, the association remained robust for the changes in VFA, VSR and SMD after adjustment for age, sex and BMI, follow-up duration, and CT manufacturers. However, the association of post-dexamethasone cortisol levels with the changes in SMA or SMI after adrenalectomy was attenuated. Neither exclusion of patients with NFAT nor exclusion of patients with overt CS altered the independent association of TA B L E 2 Changes in CT-determined visceral fat area, skeletal muscle area and muscle attenuation after adrenalectomy in patients with hypercortisolism 
| D ISCUSS I ON
In this study, we assessed the longitudinal changes in CT-determined visceral fat and skeletal muscle parameters after adrenalectomy in patients with endogenous hypercortisolism. Compared to subjects with NFAT, subjects with CS had higher VFA and lower SMA, SMI and SMD values at baseline. Reduction of visceral fat and improvement of trunk muscle mass and quality were observed at a median 1-year follow-up after adrenalectomy in patients with overt CS, compared to patients with NFAT. Of note, in patients with MACE, significant increases in SMD were observed after adrenalectomy, whereas improvements in VFA, VSR or SMA were not as evident as in patients with overt CS. Post-dexamethasone serum cortisol levels was associated with greater improvements in VFA, VSR and SMD values after adrenalectomy, but the association with changes in SMA or SMI was attenuated after adjustment for covariates.
Visceral obesity is a typical characteristic of cortisol excess and well-established cardiovascular risk factor. 1 A study reported that waist circumference was improved 1 year after surgical remission in adrenal CS. 27 In agreement with previous findings, patients with overt CS in this study had higher VFA compared to patients with NFAT or MACE at baseline, which significantly decreased 1 year after adrenalectomy. SFA was also reduced in patients with overt CS or MACE but to a lesser extent with the decrease of VSR in both groups, which supports the known preferential impact of cortisol excess on visceral fat depots. 28 Unlike for overt CS, the difference in VFA between NFAT and MACE was not clear in previous studies. [7] [8] [9] In line with these findings, we found no significant difference in baseline VFA between patients with MACE and NFAT. Prevalence of hypertension, diabetes, and dyslipidaemia was also comparable between two groups. Considering higher prevalence of hypertension and diabetes in men than in women across all age groups from epidemiologic studies, relatively higher proportion of women in MACE group compared to NFAT group (86% vs 50%) might have attenuated the expected differences in prevalence of hypertension, diabetes, and dyslipidaemia between two groups, although sex-specific differences could not be properly assessed in this study due to limited number of male patients. 29, 30 Given that we analysed patients from adrenalectomy cohort, possibility of selection bias cannot be ruled out. Because we could not measure the duration of exposure to cortisol excess in patients with MACE, cumulative effects of cortisol excess on disease severity can vary among individuals with MACE, as speculated in a prior study with similar results. 7 However, the significant decrease in VFA shown in the MACE group after adrenalectomy in this study contrasted with the continued accumulation of visceral fat observed in other studies in patients with MACE who did not undergo surgery. 9 The percent changes of VFA in patients with MACE did not statistically differ from those of patients with NFAT, which might partly be due to limited sample size or relatively short follow-up duration. However, when the severity of cortisol ex- Glucocorticoid excess affects skeletal muscle structure and function through both anti-anabolic and catabolic actions, mainly by inducing type 2 fibre atrophy. 1, 31 Approximately 42%-83% of patients with overt CS are reported to experience proximal muscle atrophy and weakness. 1, 32 Previous cross-sectional studies mainly TA B L E 3 Association of post-dexamethasone cortisol levels with changes in CT-determined visceral fat area, visceral/subcutaneous fat ratio, skeletal muscle area, skeletal muscle index and skeletal muscle radiodensity after adrenalectomy in patients with nonfunctioning adrenal tumour or hypercortisolism ΔVFA, changes in visceral fat area between baseline and follow-up (follow-up value-baseline value); ΔVSR, changes in ratio of visceral-to-subcutaneous fat area; ΔSMA, changes in skeletal muscle area; ΔSMD, changes in skeletal muscle radiodensity; ΔSMI, changes in skeletal muscle index. a Per 1-μg/dL increase in post-dexamethasone serum cortisol levels. β coefficients were adjusted for age, sex, BMI, duration of follow-up, and CT manufacturers in multivariate linear regression models. Bold presents significant P values adjusted for multiple testing using the Benjamini-Hochberg method.
focused on the association of hypercortisolism with low muscle mass. 7, 33 However, data on changes in SMD values, as a marker of muscle quality, have been limited. Lower skeletal SMD determined by CT is indicative of ectopic fat accumulation in skeletal muscle in the form of intramyocellular lipid droplets (myosteatosis). 10, 11 In this study, we found that patients with overt CS or MACE had lower skeletal muscle area compared to NFAT at baseline, in agreement with previous studies. 7, 33 Of note, SMD values also decreased in a stepwise fashion from NFAT to MACE to overt CS. When compared to patients with NFAT, the improvement in both SMA and SMD was evident at 1 year after adrenalectomy in patients with overt CS. However, in patients with MACE, SMA remained unchanged whereas SMD showed significant increase, although most of patients with MACE had clear biochemical profile of autonomous cortisol production (post-dexamethasone cortisol ≥5 μg/dL). Previous studies suggest that muscle mass or quantity may recover slowly than muscle function. A case series showed the rapid recovery of quadriceps force after adrenalectomy in a patient with adrenal CS, which did not correspond to relatively slow changes of CT-measured quadriceps cross-sectional area. 34 Similar patterns can be found in age-related changes in muscle, in that muscle strength declines more rapidly than muscle size or mass, pointing to a reduction of muscle quality. 13 Given the relatively slow recovery of muscle mass compared to muscle function, one year follow-up in this study might not be sufficient to detect full recovery of skeletal muscle structure, particularly in individuals with MACE who had subtle decrease in muscle mass compared to overt CS at baseline. However, significant changes in SMD were observed in patients with MACE even in the absence of clear muscle mass improvement. A study using cell lines and rodent models reported that glucocorticoids dysregulated intramyocellular lipid homeostasis by accumulating diacylglycerol content and increasing lipid mobilization through enhanced β-oxidation and lipolysis. 35 Ectopic fat accumulation indicated by SMD values is one factor affecting muscle quality, which is known to be associated with aging, obesity, and decreased muscle contractility. 11, 12 In light of these findings, our study suggests that myosteatosis in trunk muscles indicated by SMD values, rather than muscle mass, might play a role as an early, sensitive marker of the impact of chronic hypercortisolism on skeletal muscle, particularly in conditions of mild cortisol excess, which needs to be further validated in large, prospective investigations.
Previous studies have reported the inverse correlation between skeletal muscle mass in remission and the duration of oral glucocorticoid exposure in patients with Cushing's disease. 33 Despite the longer duration (median of 12 months) of glucocorticoid replacement after surgery in patients with overt CS compared with MACE (median of 6 months) in this study, the improvement in muscle area and radiation attenuation values was robust compared to patients with NFAT, which may be due to large differences in the severity of cortisol excess at baseline. However, in patients with MACE, even physiological doses of short-term glucocorticoid replacement might have at least partly contributed to attenuating the increase of muscle mass. 33 Nevertheless, the association of the severity of cortisol excess with VFA, VSR and SMD remained robust when the duration of hydrocortisone replacement after adrenalectomy was further adjusted in regression models.
This study has a major strength in its longitudinal study design, comparing repeated CT-based fat and muscle parameters after adrenalectomy. However, this study has several limitations. We acknowledge the inherent bias stemming from the retrospective design of this study. The classification of NFAT, MACE and overt CS may not be accurate, depending on different thresholds and criteria. However, the severity of cortisol excess was further analysed as a continuous variable using post-dexamethasone serum cortisol levels in ONDST.
The relatively small number of subjects and short-term follow-up might limit the statistical power for the detection of subtle changes or differences in outcomes, although our sample size was comparable with those of previous studies. [7] [8] [9] The measurement of VFA, SMA and SMD using single-slice CT images at the L3 level is a well-established method for cross-sectional and longitudinal comparison of body composition, with reduced costs and amounts of radiation exposure. 36 However, we acknowledge that this method may be less accurate than volumetric analysis, which was not available in this study, due to the different slice thicknesses among CT images. 36 Further prospective studies with volumetric analyses would strengthen the results. Because follow-up CT after adrenalectomy is not a standard of practice at current stage, applicability of our findings to clinical settings need to be validated in further studies. Muscle attenuation is known to vary widely between trunk muscle groups. 37 Because definitions of sarcopenia and low SMD for CT-derived L3 single slice images have not been established, we used thresholds determined from a kidney donor cohort consisted of healthy US adults, which need to be validated in association with clinical outcomes. Because the optimal region among trunk muscle groups that reflects attenuation according to cortisol excess has not been determined yet, we selected the entire trunk muscle as a region of interest for practical reasons and comparability with previous studies. Although menopause can affect fat distribution in women, information regarding menopausal status was not available in this study.
In conclusion, the severity of cortisol excess in patients with adrenal adenoma was independently associated with greater improvements in CT-measured VFA, VSR and SMD after adrenalectomy, but not with SMA or SMI. CT-measured body composition parameters, including SMD, might serve as an early, sensitive indicator for identifying who might benefit from surgical intervention, as well as a treatment response marker in patients with cortisol excess and adrenal adenoma, which merits validation in prospective studies.
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